Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
Retrieved on:
월요일, 11월 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EOS, Serum albumin, ALC, European Renal Association, MMF, Itolizumab, Safety, Ono Pharmaceutical, Dialysis, Type, Children's Organ Transplant Association, Patient, Bruce Steel, American College of Rheumatology, Novel, American College, Therapy, Lupus nephritis, Standard of care, ORR, Infection, Partnership, EGFR, CD6, S1P, EULAR, AMP, ACR, Trial of the century, Proteinuria, Pharmaceutical industry, Silviculture, Nursing, UPCR, Medicine, Lupus
“It’s important that we saw both early and large reductions in proteinuria,” said Dr.
Key Points:
- “It’s important that we saw both early and large reductions in proteinuria,” said Dr.
- Results are comparable to those observed in the Phase 3 AURORA1 study of voclosporin (ORR 70% at 6 and 12 months in active treatment).
- Consistent with the decline in UPCR overtime, subjects were able to taper their systemic corticosteroids over the course of the study.
- The poster presentation is available on the Presentations page of Equillium’s website under the Lupus tab.